Diabetes is the leading cause of kidney disease, affecting about 1 in 4 adults with the condition.1
DMX-200 for Diabetic Kidney Disease is currently in a Phase 2 clinical trial.
Diabetic Kidney Disease
There were 23 million diagnosed diabetics in the US in 2017,2 and the incidence of diabetes is estimated to grow by 54% by the year 2040.3 Diabetic Kidney Disease is progressive, and as such will ultimately lead to kidney failure and dialysis.
The best clinical marker of the rate of progression of kidney failure is an increase in protein in the urine (known as proteinuria), and a significant reduction in proteinuria demonstrates the progression of kidney failure as been slowed.
Irbesartan, the current standard of care treatment for kidney disease which has been on the market since 2001, has been shown to reduce proteinuria levels by 24% in type 2 diabetics. DMX-200, when administered to patients also taking Irbesartan, reduced proteinuria levels by a further 36%. To be clear, this 36% is in addition to the 24% already seen from Irbesartan and may result in delaying kidney failure and the need for dialysis, compared to taking Irbesartan alone.